Phase 4 IOP Signals Associated With ILUVIEN®
- Registration Number
- NCT02424019
- Lead Sponsor
- Alimera Sciences
- Brief Summary
This study will assess the safety in patients treated with ILUVIEN, with primary focus on IOP.
- Detailed Description
The specific objectives include the study of intraocular pressure (IOP) related data in patients who received ILUVIEN and how it relates to the patient's experiences following prior treatment with a course of corticosteroid which did not result in a clinically significant IOP elevation.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 153
- Patients who are eligible for treatment with ILUVIEN based on the Prescribing Information.
- Patients who are unable to understand and sign the Informed Consent Form.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description ILUVIEN 0.19 MG ILUVIEN 0.19 MG All patients will receive ILUVIEN (Fluocinolone Acetonide Intravitreal Insert) 0.19 mg.
- Primary Outcome Measures
Name Time Method Intraocular Pressure 36 months Intraocular pressure of the ILUVIEN treated eye
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (41)
Retina Consultants of Arizona
🇺🇸Phoenix, Arizona, United States
Retina Centers, P.C.
🇺🇸Tucson, Arizona, United States
Retina and Macula Institute
🇺🇸Glendale, California, United States
Atlantis Eye Care
🇺🇸Huntington Beach, California, United States
Northern California Retina Vitreous Medical Group, Inc.
🇺🇸Mountain View, California, United States
Orange County Retina Medical Group
🇺🇸Santa Ana, California, United States
Eye Care Center of Northern Colorado
🇺🇸Longmont, Colorado, United States
Retina Vitreous Associates of Florida
🇺🇸Saint Petersburg, Florida, United States
Southeast Retina Center, P.C.
🇺🇸Augusta, Georgia, United States
Retina Consultants of Hawaii
🇺🇸'Aiea, Hawaii, United States
Scroll for more (31 remaining)Retina Consultants of Arizona🇺🇸Phoenix, Arizona, United States